Humana (HUM) Earnings Date & Reports

Key Takeaways

• Adjusted EPS beat expectations: Humana posted adjusted earnings per share of $7.61, surpassing the analyst consensus estimate of approximately $7.23.
• Revenue exceeded forecasts: Quarterly revenue reached $40.89 billion, climbing 26% year-over-year and topping the consensus estimate of roughly $40.56 billion.
• GAAP guidance lowered: The company revised its full-year 2026 GAAP EPS (earnings per share under Generally Accepted Accounting Principles) guidance to "at least $6.52," down from the prior estimate of "at least $8.36."
• Membership growth accelerated: Total Medicare membership rose to 11.1 million, up from 8.2 million in the prior-year quarter, while total medical membership reached 17.9 million.
• Stock declined despite the beat: Shares fell approximately 8.7% in premarket trading as investors focused on the GAAP guidance reduction and rising benefit ratio pressures.

Earnings Context and Why It Matters

Humana's second-quarter results arrive at a pivotal moment for the managed care industry. With Medicare Advantage (MA) enrollment expanding rapidly and regulatory scrutiny intensifying around Stars quality ratings, investors are closely monitoring how major insurers balance growth with profitability. Humana entered the quarter with strong momentum following a Q1 2026 beat and reaffirmed full-year adjusted guidance in April. However, persistent headwinds from lower Stars ratings — which affect bonus payments and rebate allocations — have created a bifurcated narrative: robust top-line expansion on one side and margin compression pressures on the other. This report offered a critical check on whether Humana can maintain its growth trajectory while managing cost trends in the high single-digit range.

Reported Results

For the second quarter ended June 30, 2026, Humana reported GAAP diluted earnings per share of $5.73, with adjusted EPS of $7.61 — exceeding the consensus analyst estimate of approximately $7.23 by $0.38. Total revenue surged 26% year-over-year to $40.89 billion, driven by Medicare Advantage membership gains, higher per-member premiums from increased benchmark funding, and expanded contributions from the CenterWell healthcare services segment.

The Insurance segment — Humana's largest business unit — generated $39.1 billion in revenue and posted a GAAP benefit ratio of 91.2%, up from 89.7% in the second quarter of 2025. This increase reflected the ongoing Stars ratings revenue headwind, new individual MA members with higher initial benefit ratios, and lower expected favorable prior-period development. Operating costs declined 120 basis points year-over-year, partially offsetting the margin pressure.

Net profit reached $694 million, a 27% year-over-year increase. On a year-to-date basis, Humana reported GAAP EPS of $15.55 and adjusted EPS of $17.91. While adjusted full-year 2026 EPS guidance was affirmed at "at least $9.00" — slightly above the analyst consensus of $8.96 — the company reduced its GAAP EPS outlook, citing factors tied to the upcoming Gentiva divestiture and other non-operational adjustments.

AI Screener

For investors monitoring post-earnings opportunities in managed care and related sectors, Tickeron's AI Screener offers a powerful way to navigate shifting market conditions. This AI-driven stock and ETF discovery platform enables traders to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-generated signals. Whether identifying breakout candidates, tracking trend reversals, or scanning for fundamentally undervalued names, the screener helps users uncover trade ideas with far greater efficiency than manual research. Following an earnings event like Humana's, investors can leverage the tool to compare peer performance and spot emerging themes across the healthcare insurance landscape.

Market Reaction and Investor Sentiment

Despite delivering an adjusted earnings beat and robust revenue growth, Humana's stock came under immediate pressure following the release. Shares declined approximately 8.7% in premarket trading, reflecting investor unease over the downward revision to GAAP EPS guidance. The prior full-year GAAP estimate of "at least $8.36" had already been trimmed from earlier levels, and the further reduction to "at least $6.52" — even as adjusted guidance remained intact — appeared to amplify concerns about the widening gap between GAAP and adjusted metrics.

The rising benefit ratio also drew attention. At 91.2%, the Insurance segment's GAAP benefit ratio landed within management's guided range of slightly above 91%, yet the year-over-year increase underscored the lingering financial drag from Stars ratings headwinds. While operating cost discipline provided a partial cushion, the market's negative reaction suggests investors are increasingly focused on the durability of margins amid enrollment growth that remains tilted toward higher-cost new members.

Forward Outlook and Key Factors to Monitor

Looking ahead, Humana's reaffirmed adjusted EPS guidance of "at least $9.00" signals management's confidence in the underlying business trajectory, but several key factors will shape the remainder of fiscal 2026 and early 2027.

First, the planned exit of approximately 600,000 members in 2027 represents a deliberate strategic move to improve margin quality by shedding underperforming plans. Investors should monitor how these exits affect revenue growth rates and whether the anticipated margin expansion materializes as expected. Management has indicated that individual MA pretax margins could double this year excluding the Stars headwind, making progress on this front a critical benchmark.

Second, the Gentiva divestiture — a minority interest valued at roughly $900 million with an expected closing in Q4 2026 — will provide capital flexibility and simplify Humana's balance sheet. The transaction's impact on reported GAAP figures partly explains the guidance revision and warrants close attention when fourth-quarter results arrive.

Third, cost trends remain the central variable in the managed care equation. Humana projects full-year cost trends in the high single-digit range (7% to 8%), inclusive of medical and pharmacy expenses. Operating cost reductions of approximately 150 basis points for the full year offer a mitigating factor. Any deviation from these cost trend assumptions — particularly in inpatient utilization or prescription drug spending — could significantly sway results in coming quarters.

Finally, regulatory developments around Medicare Advantage reimbursement rates, Stars quality bonus calculations, and Part D redesign continue to influence the industry landscape. Humana's ability to execute on clinical excellence initiatives, benefit design adjustments, and recontracting efforts will determine how effectively it navigates these external pressures into 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations